Assessing Activity of Nucleoside Analogs against RNA and DNA Viruses
Dr. Liotta had developed nucleoside analogs for a variety of viral diseases and was interested in assessing their promise as new therapies against several DNA and RNA viral pathogens, including dengue, Rift Valley fever, Ebola, influenza, adenovirus, and human herpesviruses. However, he did not have the capacity in his laboratory to do multiple viral family screenings. BVGH connected Dr. Liotta and colleagues with Drs. Cassetti and Tseng, who arranged for NIH-funded contractors to test the compounds in vitro for efficacy against many DNA and RNA viral families. These projects have been funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institute of Health, Department of Health and Human Services, under contract numbers: HHSN272201100008I, HHSN272201100013I, HHSN272201100016I, and HHSN272201100019I.